ANDOVER, Mass., Aug. 01, 2017 -- MKS Instruments, Inc. (NASDAQ:MKSI), a global provider of technologies that enable advanced processes and improve productivity, today announced that its board of directors has authorized a quarterly cash dividend of $0.175 per share, payable on September 8, 2017 to shareholders of record as of August 28, 2017.
Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the company's Board of Directors.
About MKS Instruments
MKS Instruments, Inc. is a global provider of instruments, subsystems and process control solutions that measure, control, power, monitor, and analyze critical parameters of advanced manufacturing processes to improve process performance and productivity. Our products are derived from our core competencies in pressure measurement and control, flow measurement and control, gas and vapor delivery, gas composition analysis, residual gas analysis, leak detection, control technology, ozone generation and delivery, RF & DC power, reactive gas generation, vacuum technology, lasers, photonics, sub-micron positioning, vibration isolation, and optics. Our primary served markets include semiconductor capital equipment, general industrial, life sciences, and research. Additional information can be found at www.mksinst.com.
Forward-Looking Statements
This release contains projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27 of the Securities Act, and Section 21E of the Securities Exchange Act regarding MKS' future growth and the future financial performance of MKS. These projections or statements are only predictions. Actual events or results may differ materially from those in the projections or other forward-looking statements set forth herein. Readers are referred to MKS' filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for a discussion of these and other important risk factors concerning MKS and its operations. MKS is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact: Seth Bagshaw Senior Vice President and Chief Financial Officer Telephone: 978.645.5578 Email: [email protected] Investor Relations Contact: Monica Gould The Blueshirt Group Telephone: 212.871.3927 Email: [email protected] Lindsay Savarese The Blueshirt Group Telephone: 212-331-8417 Email: [email protected]


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



